Literature DB >> 11078466

Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy.

C Vigouroux1, J Magré, M C Vantyghem, C Bourut, O Lascols, S Shackleton, D J Lloyd, B Guerci, G Padova, P Valensi, A Grimaldi, R Piquemal, P Touraine, R C Trembath, J Capeau.   

Abstract

Missense mutations of the lamin A/C gene, LMNA, have been recently identified in Dunnigan-type familial partial lipodystrophy (FPLD), which belongs to a heterogeneous group of rare disorders affecting adipose tissue distribution and metabolism. In this study, we sequenced the LMNA coding region from patients presenting with FPLD or other forms of lipodystrophy. We identified two heterozygous mutations in exon 8, R482W and R482Q, in FPLD patients (six families and one individual) with various clinical presentations. In addition, we found a novel heterozygous mutation (R584H) in exon 11, encoding specifically the lamin A isoform, in a patient with typical FPLD. Clinical and biochemical investigations in FPLD patients revealed that the expression and the severity of the phenotype were markedly dependent on sex, with female patients being more markedly affected. In subjects with generalized lipoatrophy, either congenital (13 case subjects) or acquired (14 case subjects), or Barraquer-Simon syndrome (2 case subjects), the entire LMNA coding sequence was normal. Although FPLD mutations are predominantly localized in exon 8 of LMNA, the finding of a novel mutation at codon 584, together with the R582H heterozygous substitution recently described, confirms that the C-terminal region specific to the lamin A isoform is a second susceptibility region for mutations in FPLD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11078466     DOI: 10.2337/diabetes.49.11.1958

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  32 in total

Review 1.  Nuclear mechanics in disease.

Authors:  Monika Zwerger; Chin Yee Ho; Jan Lammerding
Journal:  Annu Rev Biomed Eng       Date:  2011-08-15       Impact factor: 9.590

Review 2.  Mouse models of the laminopathies.

Authors:  Colin L Stewart; Serguei Kozlov; Loren G Fong; Stephen G Young
Journal:  Exp Cell Res       Date:  2007-03-31       Impact factor: 3.905

Review 3.  What the genetics of lipodystrophy can teach us about insulin resistance and diabetes.

Authors:  Camille Vatier; Guillaume Bidault; Nolwenn Briand; Anne-Claire Guénantin; Laurence Teyssières; Olivier Lascols; Jacqueline Capeau; Corinne Vigouroux
Journal:  Curr Diab Rep       Date:  2013-12       Impact factor: 4.810

Review 4.  Laminopathies and the long strange trip from basic cell biology to therapy.

Authors:  Howard J Worman; Loren G Fong; Antoine Muchir; Stephen G Young
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

Review 5.  Diseases of the nuclear envelope.

Authors:  Howard J Worman; Cecilia Ostlund; Yuexia Wang
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

6.  LMNA mutations induce a non-inflammatory fibrosis and a brown fat-like dystrophy of enlarged cervical adipose tissue.

Authors:  Véronique Béréziat; Pascale Cervera; Caroline Le Dour; Marie-Christine Verpont; Sylvie Dumont; Marie-Christine Vantyghem; Jacqueline Capeau; Corinne Vigouroux
Journal:  Am J Pathol       Date:  2011-09-21       Impact factor: 4.307

7.  Clinical Utility Gene Card for: Familial partial lipodystrophy.

Authors:  Isabelle Jéru; Camille Vatier; David Araujo-Vilar; Corinne Vigouroux; Olivier Lascols
Journal:  Eur J Hum Genet       Date:  2016-08-03       Impact factor: 4.246

Review 8.  Lamins and Lamin-Associated Proteins in Gastrointestinal Health and Disease.

Authors:  Graham F Brady; Raymond Kwan; Juliana Bragazzi Cunha; Jared S Elenbaas; M Bishr Omary
Journal:  Gastroenterology       Date:  2018-03-13       Impact factor: 22.682

9.  Myopathic lamin mutations impair nuclear stability in cells and tissue and disrupt nucleo-cytoskeletal coupling.

Authors:  Monika Zwerger; Diana E Jaalouk; Maria L Lombardi; Philipp Isermann; Monika Mauermann; George Dialynas; Harald Herrmann; Lori L Wallrath; Jan Lammerding
Journal:  Hum Mol Genet       Date:  2013-02-19       Impact factor: 6.150

10.  Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation.

Authors:  Jean-Marc Guettier; Jean Y Park; Elaine K Cochran; Christine Poitou; Arnaud Basdevant; Muriel Meier; Karine Clément; Jocelyne Magré; Phillip Gorden
Journal:  Clin Endocrinol (Oxf)       Date:  2007-12-10       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.